1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Bioepis Clears Up Second EU Bevacizumab Application

Market Entry Also Confirmed For Aybintio Biosimilar

 
• By Dean Rudge

Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.

Europe_Night
Samsung Bioepis' Onbevzi biosimilar has been backed for a Europe-wide MA • Source: Shutterstock

Samsung Bioepis’ second biosimilar rival to Avastin (bevacizumab) to be recommended for approval in Europe is a duplicate application, the Korean firm has confirmed to Generics Bulletin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products